A high-quality body of evidence supports the use of aspirin in reducing sporadic and hereditary adenomatous polyps, and numerous observational studies point to a reduction in colorectal cancer (CRC) risk. However, using aspirin as an adjuvant therapy in established CRC was until recently inconceivable. Now, evidence from both observational and clinical trials of aspirin for other indications suggests that aspirin initiation after (or before) the diagnosis of CRC improves CRC-specific mortalit...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record